Chemistry:RWJ-51204

From HandWiki
Short description: Chemical compound
RWJ-51204
RWJ-51204.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H19F2N3O3
Molar mass399.398 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

RWJ-51204 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.

RWJ-51204 is a nonselective partial agonist at GABAA receptors.[1] It produces primarily anxiolytic effects at low doses, with sedative, ataxia and muscle relaxant effects only appearing at some 20x the effective anxiolytic dose.[2] It was discovered by researchers at the pharmaceutical company Johnson & Johnson,[3][4] but its development has been discontinued.

References

  1. "Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.". Current Drug Targets. CNS and Neurological Disorders 2 (4): 213–32. August 2003. doi:10.2174/1568007033482841. PMID 12871032. 
  2. "5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic". The Journal of Pharmacology and Experimental Therapeutics 303 (2): 777–90. November 2002. doi:10.1124/jpet.102.036954. PMID 12388665. 
  3. Reitz AB, Jordan AD, Sanfilippo PJ, Vavouyios-Smith A, US patent 5817668, issued 6 October 1998, assigned to Ortho Pharma Corp
  4. "Process research for the synthesis of RWJ-51204, a novel anxiolytic agent.". Organic Process Research & Development 3 (4): 260–265. 1999. doi:10.1021/op990182l.